Compare ASTL & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | PACB |
|---|---|---|
| Founded | 1902 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.0M | 419.8M |
| IPO Year | N/A | 2010 |
| Metric | ASTL | PACB |
|---|---|---|
| Price | $4.14 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.13 |
| AVG Volume (30 Days) | 1.4M | ★ 5.5M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.22 |
| Revenue Next Year | $25.68 | $12.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $3.02 | $0.85 |
| 52 Week High | $7.25 | $2.73 |
| Indicator | ASTL | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 50.74 | 42.10 |
| Support Level | $3.99 | $1.19 |
| Resistance Level | $4.29 | $1.40 |
| Average True Range (ATR) | 0.24 | 0.08 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 82.45 | 50.00 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.